List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6231167/publications.pdf Version: 2024-02-01



HENDIK COÃOEN

#	Article	IF	CITATIONS
1	The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c. Pharmacogenetics and Genomics, 2011, 21, 837-850.	1.5	216
2	<i>mdr-1</i> Single Nucleotide Polymorphisms in Ovarian Cancer Tissue: G2677T/A Correlates with Response to Paclitaxel Chemotherapy. Clinical Cancer Research, 2006, 12, 854-859.	7.0	150
3	Pharmacogenetic Studies of Paclitaxel in the Treatment of Ovarian Cancer. Basic and Clinical Pharmacology and Toxicology, 2009, 104, 130-137.	2.5	111
4	A reassessment of DNA-immunoprecipitation-based genomic profiling. Nature Methods, 2018, 15, 499-504.	19.0	92
5	Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics Journal, 2011, 11, 113-120.	2.0	81
6	In Vitro and In Vivo Metabolite Identification Studies for the New Synthetic Opioids Acetylfentanyl, Acrylfentanyl, Furanylfentanyl, and 4-Fluoro-Isobutyrylfentanyl. AAPS Journal, 2017, 19, 1102-1122.	4.4	76
7	Polymorphisms in the ABCB1 gene and effect on outcome and toxicity in childhood acute lymphoblastic leukemia. Pharmacogenomics Journal, 2015, 15, 372-379.	2.0	74
8	Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. European Journal of Clinical Pharmacology, 2011, 67, 693-700.	1.9	70
9	Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. Journal of Medical Genetics, 2013, 50, 599-605.	3.2	67
10	Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy. Clinical Cancer Research, 2012, 18, 4441-4448.	7.0	61
11	Real world evidence on gemcitabine and nab-paclitaxel combination chemotherapy in advanced pancreatic cancer. BMC Cancer, 2019, 19, 40.	2.6	53
12	Increased <i>Rrm2</i> gene dosage reduces fragile site breakage and prolongs survival of ATR mutant mice. Genes and Development, 2015, 29, 690-695.	5.9	51
13	Identification of AKB-48 and 5F-AKB-48 Metabolites in Authentic Human Urine Samples Using Human Liver Microsomes and Time of Flight Mass Spectrometry. Journal of Analytical Toxicology, 2015, 39, 426-435.	2.8	46
14	ABCB1 G1199A Polymorphism and Ovarian Cancer Response to Paclitaxel. Journal of Pharmaceutical Sciences, 2008, 97, 2045-2048.	3.3	44
15	Pharmacogenetics, Plasma Concentrations, Clinical Signs and EEG During Propofol Treatment. Basic and Clinical Pharmacology and Toxicology, 2014, 115, 565-570.	2.5	43
16	CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. European Journal of Clinical Pharmacology, 2010, 66, 383-386.	1.9	41
17	5Fâ€MDMBâ€₽ICA metabolite identification and cannabinoid receptor activity. Drug Testing and Analysis, 2020, 12, 127-135.	2.6	41
18	Identification of ABâ€FUBINACA metabolites in authentic urine samples suitable as urinary markers of drug intake using liquid chromatography quadrupole tandem time of flight mass spectrometry. Drug Testing and Analysis, 2016, 8, 950-956.	2.6	40

#	Article	IF	CITATIONS
19	Fatal Poisonings Associated with New Psychoactive Substances. Handbook of Experimental Pharmacology, 2018, 252, 495-541.	1.8	40
20	Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype. Pharmacogenomics Journal, 2012, 12, 111-118.	2.0	38
21	Whole-genome sequencing of human remains to enable genealogy DNA database searches – A case report. Forensic Science International: Genetics, 2020, 46, 102233.	3.1	38
22	Impact of <i>ABCB1</i> Variants on Neutrophil Depression: A Pharmacogenomic Study of Paclitaxel in 92 Women with Ovarian Cancer. Basic and Clinical Pharmacology and Toxicology, 2012, 110, 199-204.	2.5	36
23	Mutations in the isocitrate dehydrogenase 2 gene and IDH1 SNP 105C > T have a prognostic value in acute myeloid leukemia. Biomarker Research, 2014, 2, 18.	6.8	36
24	Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line. Pharmacogenetics and Genomics, 2014, 24, 52-61.	1.5	34
25	Influence of Cremophor EL and Genetic Polymorphisms on the Pharmacokinetics of Paclitaxel and Its Metabolites Using a Mechanism-Based Model. Drug Metabolism and Disposition, 2011, 39, 247-255.	3.3	32
26	Identifying Metabolites of Meclonazepam by High-Resolution Mass Spectrometry Using Human Liver Microsomes, Hepatocytes, a Mouse Model, and Authentic Urine Samples. AAPS Journal, 2017, 19, 736-742.	4.4	30
27	The metabolism of the synthetic cannabinoids ADBâ€BUTINACA and ADBâ€4enâ€PINACA and their detection in forensic toxicology casework and infused papers seized in prisons. Drug Testing and Analysis, 2022, 14, 634-652.	2.6	30
28	Measurement of paclitaxel and its metabolites in human plasma using liquid chromatography/ion trap mass spectrometry with a sonic spray ionization interface. Rapid Communications in Mass Spectrometry, 2006, 20, 2183-2189.	1.5	28
29	Decreased survival in normal karyotype AML with singleâ€nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5′â€nucleotidase. American Journal of Hematology, 2013, 88, 1001-1006.	4.1	28
30	Looking at flubromazolam metabolism from four different angles: Metabolite profiling in human liver microsomes, human hepatocytes, mice and authentic human urine samples with liquid chromatography high-resolution mass spectrometry. Forensic Science International, 2017, 274, 55-63.	2.2	28
31	A validated liquid chromatography tandem mass spectrometry method for quantification of erlotinib, OSI-420 and didesmethyl erlotinib and semi-quantification of erlotinib metabolites in human plasma. Journal of Pharmaceutical and Biomedical Analysis, 2015, 107, 186-195.	2.8	25
32	Validation and Cross-Reactivity Data for Fentanyl Analogs With the Immunalysis Fentanyl ELISA. Journal of Analytical Toxicology, 2019, 43, 18-24.	2.8	25
33	Biotransformation of the New Synthetic Cannabinoid with an Alkene, MDMB-4en-PINACA, by Human Hepatocytes, Human Liver Microsomes, and Human Urine and Blood. AAPS Journal, 2020, 22, 13.	4.4	25
34	Impact of CYP3A5*3 and CYP2C8-HapC on Paclitaxel/Carboplatin-Induced Myelosuppression in Patients with Ovarian Cancer. Journal of Pharmaceutical Sciences, 2011, 100, 4205-4209.	3.3	24
35	GWAS-based association between <i>RWDD3</i> and <i>TECTA</i> variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients. Acta OncolÃ ³ gica, 2013, 52, 871-873.	1.8	24
36	Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases. Pharmacogenomics Journal, 2015, 15, 165-171.	2.0	24

#	Article	IF	CITATIONS
37	Correlations between metabolism and structural elements of the alicyclic fentanyl analogs cyclopropyl fentanyl, cyclobutyl fentanyl, cyclopentyl fentanyl, cyclohexyl fentanyl and 2,2,3,3-tetramethylcyclopropyl fentanyl studied by human hepatocytes and LC-QTOF-MS. Archives of Toxicology, 2019, 93, 95-106.	4.2	24
38	Expression Patterns of 17β-Hydroxysteroid Dehydrogenase 14 in Human Tissues. Hormone and Metabolic Research, 2012, 44, 949-956.	1.5	21
39	Melanin Inhibits Cytotoxic Effects of Doxorubicin and Daunorubicin in MOLT 4 Cells. Pigment Cell & Melanoma Research, 2003, 16, 351-354.	3.6	20
40	Effects of nicotine, its metabolites and tobacco extracts on human platelet function in vitro. Toxicology in Vitro, 2013, 27, 932-938.	2.4	20
41	Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities. Clinical Cancer Research, 2016, 22, 366-373.	7.0	20
42	The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo. Biochemical and Biophysical Research Communications, 2011, 414, 563-568.	2.1	19
43	Assessment of HaloPlex Amplification for Sequence Capture and Massively Parallel Sequencing of Arrhythmogenic Right Ventricular Cardiomyopathy–Associated Genes. Journal of Molecular Diagnostics, 2015, 17, 31-42.	2.8	19
44	Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: Novel treatment predictive factors identified. Cancer Letters, 2011, 313, 145-153.	7.2	18
45	ABCB1 gene polymorphisms are associated with fatal intoxications involving venlafaxine but not citalopram. International Journal of Legal Medicine, 2013, 127, 579-586.	2.2	18
46	ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro. Pharmacogenomics and Personalized Medicine, 2013, 6, 63.	0.7	18
47	Role of cytochrome P450 <i>2C8*3</i> (<i>CYP2C8*3</i>) in paclitaxel metabolism and paclitaxel-induced neurotoxicity. Pharmacogenomics, 2015, 16, 929-937.	1.3	17
48	Monozygotic twins with myocarditis and a novel likely pathogenic desmoplakin gene variant. ESC Heart Failure, 2020, 7, 1210-1216.	3.1	17
49	Targeted Sequencing Reveals Low-Frequency Variants in <i>EPHA</i> Genes as Markers of Paclitaxel-Induced Peripheral Neuropathy. Clinical Cancer Research, 2017, 23, 1227-1235.	7.0	16
50	Pharmacogenetic study of the impact of ABCB1 single-nucleotide polymorphisms on lenalidomide treatment outcomes in patients with multiple myeloma: results from a phase IV observational study and subsequent phase II clinical trial. Cancer Chemotherapy and Pharmacology, 2018, 81, 183-193.	2.3	16
51	Enantioselective pharmacokinetics of tramadol and its three main metabolites; impact of <i>CYP2D6</i> , <i> CYP2B6</i> , and <i>CYP3A4</i> genotype. Pharmacology Research and Perspectives, 2018, 6, e00419.	2.4	16
52	Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues. Gene, 2012, 506, 62-68.	2.2	15
53	Pharmacogenomics of importance for paclitaxel chemotherapy. Pharmacogenomics, 2008, 9, 671-674.	1.3	14
54	Histone H1 interphase phosphorylation becomes largely established in G1 or early S phase and differs in G1 between T-lymphoblastoid cells and normal T cells. Epigenetics and Chromatin, 2011, 4, 15.	3.9	14

#	Article	IF	CITATIONS
55	Metabolism study for CUMYLâ€4CNâ€BINACA in human hepatocytes and authentic urine specimens: Free cyanide is formed during the main metabolic pathway. Drug Testing and Analysis, 2018, 10, 1270-1279.	2.6	14
56	LC-QTOF-MS Identification of Major Urinary Cyclopropylfentanyl Metabolites Using Synthesized Standards. Journal of Analytical Toxicology, 2019, 43, 607-614.	2.8	14
57	ABCB1 gene polymorphisms are associated with suicide in forensic autopsies. Pharmacogenetics and Genomics, 2013, 23, 463-469.	1.5	13
58	Impact of <i><scp>ABCB</scp>1</i> single nucleotide polymorphisms 1236C>T and 2677G>T on overall survival in <i><scp>FLT</scp>3</i> wildâ€type <i>de novo </i> <scp>AML</scp> patients with normal karyotype. British Journal of Haematology, 2014, 167, 671-680.	2.5	13
59	<i><scp>TP</scp>53</i> mutations and <i>MDM2</i> ^{SNP309} identify subgroups of <scp>AML</scp> patients with impaired outcome. European Journal of Haematology, 2015, 94, 355-362.	2.2	13
60	The congenital disorder of glycosylation in PGM1 (PGM1-CDG) can cause severe cardiomyopathy and unexpected sudden cardiac death in childhood. Forensic Science International: Genetics, 2019, 43, 102111.	3.1	12
61	The use of FTA cards to acquire DNA profiles from postmortem cases. International Journal of Legal Medicine, 2019, 133, 1651-1657.	2.2	12
62	Metabolism of MMB022 and identification of dihydrodiol formation in vitro using synthesized standards. Drug Testing and Analysis, 2020, 12, 1432-1441.	2.6	12
63	Structure Elucidation of Urinary Metabolites of Fentanyl and Five Fentanyl Analogs using LC-QTOF-MS, Hepatocyte Incubations and Synthesized Reference Standards. Journal of Analytical Toxicology, 2021, 44, 993-1003.	2.8	12
64	In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia. Therapeutic Drug Monitoring, 2016, 38, 230-238.	2.0	11
65	Synthesis and identifications of potential metabolites as biomarkers of the synthetic cannabinoid AKB-48. Tetrahedron, 2018, 74, 2905-2913.	1.9	11
66	Heroin-Related Compounds and Metabolic Ratios in Postmortem Samples Using LC–MS-MS. Journal of Analytical Toxicology, 2021, 45, 215-225.	2.8	11
67	Post-Mortem Metabolomics: A Novel Approach in Clinical Biomarker Discovery and a Potential Tool in Death Investigations. Chemical Research in Toxicology, 2021, 34, 1496-1502.	3.3	11
68	Spontaneous Reversal of P-Glycoprotein Expression in Multidrug Resistant Cell Lines*. Basic and Clinical Pharmacology and Toxicology, 2003, 93, 297-304.	0.0	10
69	<i><scp>ABCB</scp>1</i> Variation Affects Myelosuppression, Progressionâ€free Survival and Overall Survival in Paclitaxel/Carboplatinâ€treated Ovarian Cancer Patients. Basic and Clinical Pharmacology and Toxicology, 2018, 123, 277-287.	2.5	10
70	Metabolite Profiling of Ortho-, Meta- and Para-Fluorofentanyl by Hepatocytes and High-Resolution Mass Spectrometry. Journal of Analytical Toxicology, 2020, 44, 140-148.	2.8	10
71	Clinical characteristics and blood/serum bound prognostic biomarkers in advanced pancreatic cancer treated with gemcitabine and nab-paclitaxel. BMC Cancer, 2020, 20, 950.	2.6	10
72	In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT1A, and 5-HT2A receptors—On-target receptor potency and efficacy, and off-target effects. Forensic Science International, 2020, 317, 110553.	2.2	10

#	Article	IF	CITATIONS
73	High ECG Risk-Scores Predict Late Gadolinium Enhancement on Magnetic Resonance Imaging in HCM in the Young. Pediatric Cardiology, 2021, 42, 492-500.	1.3	10
74	Assessment of Whole Genome Amplification for Sequence Capture and Massively Parallel Sequencing. PLoS ONE, 2014, 9, e84785.	2.5	10
75	Characterization of recent non-fentanyl synthetic opioids via three different in vitro µ-opioid receptor activation assays. Archives of Toxicology, 2022, 96, 877-897.	4.2	10
76	β-Tubulin mutations in ovarian cancer using single strand conformation analysis-risk of false positive results from paraffin embedded tissues. Cancer Letters, 2006, 236, 148-154.	7.2	9
77	Replication of Genetic Polymorphisms Reported to Be Associated with Taxane-Related Sensory Neuropathy in Patients with Early Breast Cancer Treated with Paclitaxel—Letter. Clinical Cancer Research, 2015, 21, 3092-3093.	7.0	9
78	Determination of loss of consciousness. European Journal of Anaesthesiology, 2016, 33, 922-928.	1.7	9
79	ABCB1 single-nucleotide variants and survival in patients with glioblastoma treated with radiotherapy concomitant with temozolomide. Pharmacogenomics Journal, 2020, 20, 213-219.	2.0	9
80	Whole-genome sequencing and gene network modules predict gemcitabine/carboplatin-induced myelosuppression in non-small cell lung cancer patients. Npj Systems Biology and Applications, 2020, 6, 25.	3.0	9
81	Hereditary Hypertrophic Cardiomyopathy in Children and Young Adults—The Value of Reevaluating and Expanding Gene Panel Analyses. Genes, 2020, 11, 1472.	2.4	9
82	The pan-ErbB tyrosine kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell leukemia (Jurkat) cells. Biochemical and Biophysical Research Communications, 2011, 410, 422-427.	2.1	8
83	Simple and cost-effective liquid chromatography-mass spectrometry method to measure dabrafenib quantitatively and six metabolites semi-quantitatively in human plasma. Analytical and Bioanalytical Chemistry, 2017, 409, 3749-3756.	3.7	8
84	Erlotinib treatment induces cytochrome P450 3A activity in nonâ€small cell lung cancer patients. British Journal of Clinical Pharmacology, 2019, 85, 1704-1709.	2.4	8
85	Irreversible panâ€ERBB inhibitor canertinib elicits antiâ€ŀeukaemic effects and induces the regression of FLT3â€ITD transformed cells in mice. British Journal of Haematology, 2011, 155, 198-208.	2.5	7
86	Genes and variants in hematopoiesis-related pathways are associated with gemcitabine/carboplatin-induced thrombocytopenia. Pharmacogenomics Journal, 2020, 20, 179-191.	2.0	7
87	Activation of the μâ€opioid receptor by alicyclic fentanyls: Changes from high potency full agonists to low potency partial agonists with increasing alicyclic substructure. Drug Testing and Analysis, 2021, 13, 169-174.	2.6	7
88	Persistent neuropathy among early-stage breast cancer survivors in a population-based cohort. British Journal of Cancer, 2021, 125, 445-457.	6.4	7
89	Novel rapid liquid chromatography tandem masspectrometry method for vemurafenib and metabolites in human plasma, including metabolite concentrations at steady state. Biomedical Chromatography, 2016, 30, 1234-1239.	1.7	6
90	Synthesis and identification of an important metabolite of AKB-48 with a secondary hydroxyl group on the adamantyl ring. Tetrahedron Letters, 2017, 58, 1456-1458.	1.4	6

#	Article	IF	CITATIONS
91	Metabolism of the benzodiazepines norflurazepam, flurazepam, fludiazepam and cinolazepam by human hepatocytes using high-resolution mass spectrometry and distinguishing their intake in authentic urine samples. Forensic Toxicology, 2020, 38, 79-94.	2.4	6
92	Circumstances, Postmortem Findings, Blood Concentrations and Metabolism in a Series of Methoxyacetylfentanyl-Related Deaths. Journal of Analytical Toxicology, 2021, 45, 760-771.	2.8	6
93	Comparison of two types of population pharmacokinetic model structures of paclitaxel. European Journal of Pharmaceutical Sciences, 2008, 33, 128-137.	4.0	5
94	Genetic association of gemcitabine/carboplatin-induced leukopenia and neutropenia in non-small cell lung cancer patients using whole-exome sequencing. Lung Cancer, 2020, 147, 106-114.	2.0	5
95	Oxycodone Concentrations and Metabolic Ratios in Femoral Blood from Fatal Intoxications and Other Causes of Death using LC–MS-MS. Journal of Analytical Toxicology, 2021, 45, 124-133.	2.8	5
96	Association of CYP2B6 Genotype with Survival and Progression Free Survival in Cyclophosphamide Treated Multiple Myeloma. Journal of Cancer Therapy, 2012, 03, 20-27.	0.4	5
97	JMJD1C knockdown affects myeloid cell lines proliferation, viability, and gemcitabine/carboplatin-sensitivity. Pharmacogenetics and Genomics, 2021, 31, 60-67.	1.5	5
98	Putting Designer Drugs Back in Pandora's Box: Analytical Challenges and Metabolite Identification. Clinical Chemistry, 2016, 62, 4-5.	3.2	4
99	Oxycodone findings and CYP2D6 function in postmortem cases. Forensic Science International: Genetics, 2021, 53, 102510.	3.1	4
100	Real-world evaluation of upfront docetaxel in metastatic castration-sensitive prostate cancer. World Journal of Clinical Oncology, 2021, 12, 1009-1022.	2.3	4
101	Postmortem Metabolomics Reveal Acylcarnitines as Potential Biomarkers for Fatal Oxycodone-Related Intoxication. Metabolites, 2022, 12, 109.	2.9	4
102	The Importance of BHB Testing on the Post-Mortem Diagnosis of Ketoacidosis. Biomolecules, 2022, 12, 9.	4.0	4
103	Semi-physiologically based pharmacokinetic modeling of paclitaxel metabolism and in silico-based study of the dynamic sensitivities in pathway kinetics. European Journal of Pharmaceutical Sciences, 2012, 47, 759-767.	4.0	3
104	Assessing the GeneRead SNP panel for analysis of low-template and PCR-inhibitory samples. Forensic Science International: Genetics Supplement Series, 2017, 6, e267-e269.	0.3	3
105	The influence of ABCG2 polymorphism on erlotinib efflux in the K562 cell line. Pharmacology Research and Perspectives, 2020, 8, e00581.	2.4	3
106	Characteristics of post-mortem beta-hydroxybutyrate-positivet cases – A retrospective study on age, sex and BMI in 1407 forensic autopsies. Forensic Science International, 2021, 325, 110878.	2.2	3
107	Validation of whole genome amplification for analysis of the p53 tumor suppressor gene in limited amounts of tumor samples. Biochemical and Biophysical Research Communications, 2012, 425, 379-383.	2.1	2
108	MTR-09ABCB1 AS PREDICTIVE MARKER FOR POOR SURVIVAL IN PATIENTS WITH GLIOBLASTOMA TREATED WITH RADIOTHERAPY AND CONCOMITANT AND ADJUVANT TEMOZOLOMIDE. Neuro-Oncology, 2015, 17, v126.1-v126.	1.2	2

#	Article	IF	CITATIONS
109	The Quantification of Oxycodone and Its Phase I and II Metabolites in Urine. Journal of Analytical Toxicology, 2022, 46, 55-63.	2.8	2
110	Single-Cell RNA Sequencing of Hematopoietic Stem and Progenitor Cells Treated with Gemcitabine and Carboplatin. Genes, 2020, 11, 549.	2.4	2
111	Technical in-depth comparison of two massive parallel DNA-sequencing methods for formalin-fixed paraffin-embedded tissue from victims of sudden cardiac death. Forensic Science International: Genetics, 2021, 53, 102522.	3.1	2
112	Oxycodone-Related Deaths: The Significance of Pharmacokinetic and Pharmacodynamic Drug Interactions. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 259.	1.6	2
113	A sensitive LC-MS/MS method for the quantitation of oxycodone, noroxycodone, 6α-oxycodol, 6β-oxycodol, oxymorphone, and noroxymorphone in human blood. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1171, 122625.	2.3	1
114	Functional Characterization of ABCG2 Polymorphisms and Their Influence on Tyrosine Kinase Inhibitor Effects in Chronic Myeloid Leukemia Cells,. Blood, 2011, 118, 3495-3495.	1.4	1
115	The association of four genetic variants with myelosuppression in gemcitabineâ€treated Japanese is not evident in gemcitabine/carboplatinâ€treated Swedes. Basic and Clinical Pharmacology and Toxicology, 2022, , .	2.5	1
116	A validated and rapid high-performance liquid chromatography method for the quantification of conversion of radio-labelled sex steroids. Hormone Molecular Biology and Clinical Investigation, 2010, 3, 375-81.	0.7	0
117	Microtubule-targeting drugs and personalization of cancer treatment. Pharmacogenomics, 2011, 12, 449-451.	1.3	0
118	Implications On Drug Resistance and Survival of ABCB1 Single Nucleotide Polymorphisms in Normal Karyotype De Novo AML Blood, 2009, 114, 2648-2648.	1.4	0
119	Abstract 2757: NT5C2 single nucleotide polymorphisms affects survival and response inde novoAML patients with normal karyotype. , 2010, , .		Ο
120	Abstract 814: P-glycoprotein transport of the active imatinib metabolite, CGP74588, in chronic myeloid leukemia cells. , 2012, , .		0
121	Abstract 5596: Altered efficacy of tyrosine kinase inhibitors in chronic myeloid leukemia cells expressing wild type or polymorphic ABCG2. , 2012, , .		Ο
122	Histone (H1) Phosphorylation. , 2013, , 155-189.		0
123	Abstract 1170: Correlation between cytidine deaminase single nucleotide polymorphisms andin vitrodrug sensitivity, DNA methylation and outcome in normal karyotype acute myelogenous leukemia , 2013, , .		0
124	IDH1 and IDH2 Mutations Are Frequent Genetic Alterations In Cytogenetically Normal Acute Myeloid Leukemia With Adverse Outcome. Blood, 2013, 122, 3894-3894.	1.4	0
125	Abstract 3518: TP53 mutations and MDM2 single nucleotide polymorphism 309T-G predicts outcome and treatment resistance in acute myeloid leukemia. , 2014, , .		0
126	Abstract 5026: Association to drug-induced leukopenia using whole-exome sequencing of non-small cell lung cancer patients on gemcitabine/carboplatin regimen. , 2017, , .		0

#	Article	IF	CITATIONS
127	Abstract 5030: The impact of ABCB1 single nucleotide polymorphisms on the outcome in lenalidomide treated multiple myeloma patients. , 2017, , .		0
128	Abstract 5028: Whole exome sequencing and genetic association of gemcitabine/carboplatin induced thrombocytopenia in non-small cell lung cancer patients. , 2017, , .		0
129	An improved procedure for the synthesis of fourteen 4-OH and 3-MeO-4OH metabolites of fentanyl analogues from two intermediates on multi-gram scale. Synthetic Communications, 0, , 1-10.	2.1	0
130	Urinary Pharmacokinetics of Immediate and Controlled Release Oxycodone and its Phase I and II Metabolites Using LC–MS-MS. Journal of Analytical Toxicology, 2021, , .	2.8	0